Ahlawat, A, Solanki, N, Singh, SK, Dua, K & Dureja, H 2025, 'Senolytics' in Advanced Drug Delivery Systems in Management of Chronic Obstructive Pulmonary Disease, CRC Press, pp. 190-204.
View/Download from: Publisher's site
Aljabali, AAA, Obeid, MA, Dua, K & Tambuwala, MM 2025, 'Targeted delivery via nucleic acid–functionalized gold nanoparticles' in Intelligent Nanobiosystems in Medicine and Healthcare, Volume 1, Elsevier, pp. 65-81.
View/Download from: Publisher's site
Babu, MR, Guptha, PM, Yanadaiah, P, Vishwas, S, Gulati, M, Dua, K & Singh, SK 2025, 'Prospects of novel drug delivery systems in treating cerebral palsy' in Novel Drug Delivery Systems in the management of CNS Disorders, Elsevier, pp. 269-276.
View/Download from: Publisher's site
Bhat, AA, Afzal, M, Thapa, R, Hussain, MS, Singla, N, Rawat, S, Khan, A, B., T, S., R, Singh, SK, Dua, K & Gupta, G 2025, 'Nickel and lung cancer' in Lung Cancer and Environmental Toxicants, Elsevier, pp. 141-157.
View/Download from: Publisher's site
Bisht, D, Joshi, DC, Bisht, M, Joshi, N, Azizov, S, Lalhlenmawia, H, Kumar, D, Dua, K, Shetty, SR & Suares, D 2025, 'Natural product-based compounds for chronic respiratory disorders' in Technological Advances and Innovations in the Treatment of Chronic Respiratory Disorders, Elsevier, pp. 309-333.
View/Download from: Publisher's site
Chawla, PA, Singh, D, Singh, A, Amisha, Raj, ND, Chawla, V & Dua, K 2025, 'Role of novel drug delivery systems in delivering antidepressant drugs to the brain' in Novel Drug Delivery Systems in the management of CNS Disorders, Elsevier, pp. 235-245.
View/Download from: Publisher's site
Corrie, L, Gulati, M, Vishwas, S, Khursheed, R, Kaur, J, Dua, K & Singh, SK 2025, 'Regulatory aspect of nanomedicines and nanobiosystems development' in Intelligent Nanobiosystems in Medicine and Healthcare, Volume 1, Elsevier, pp. 303-327.
View/Download from: Publisher's site
De Rubis, G, MacLoughlin, R, Santos, HA, Shetty, S, Suares, D & Dua, K 2025, 'Preface' in Technological Advances and Innovations in the Treatment of Chronic Respiratory Disorders, Elsevier, pp. xxi-xxii.
View/Download from: Publisher's site
Disouza, J, Kumbhar, P, Gandhi, S, Kamble, V, Karade, P, Kumar Singh, S, Ajit Kolekar, K, Dua, K & Patravale, V 2025, 'Formulation Optimization and Design of SNEDDS' in Application of Self-Nanoemulsifying Drug Delivery Systems in Inflammatory Diseases, CRC Press, pp. 54-72.
View/Download from: Publisher's site
Gupta, G, Afzal, M, Hussain, MS, Bhat, AA, Thapa, R, Raihan, M, Arora, P, Negi, P, Chellappan, DK, Dureja, H, Singh, SK, Dua, K & Subramaniyan, V 2025, 'Environmental toxicants' in Lung Cancer and Environmental Toxicants, Elsevier, pp. 17-31.
View/Download from: Publisher's site
Gupta, G, Hussain, MS, Maqbool, M, Bhat, AA, Thapa, R, Rawat, S, Gupta, S, Roshan, S, Chellappan, DK, Singh, SK, Dua, K & Saeid, AB 2025, 'Phthalates and the Gut Microbiome' in Gut Microbiome and Environmental Toxicants, CRC Press, pp. 86-108.
View/Download from: Publisher's site
Kumar, R, Singh, A, Kapoor, B, Hussain, MS, Singh, SK, Dua, K, Dureja, H, Thomas, NV & Gulati, M 2025, 'Nose to brain drug delivery through advanced drug delivery systems' in Novel Drug Delivery Systems in the management of CNS Disorders, Elsevier, pp. 105-119.
View/Download from: Publisher's site
Mishra, R, Afzal, M, Hussain, MS, Bhat, AA, Thapa, R, Siddique, R, Patel, N, Rawat, S, Gupta, S, Singh, SK, Dua, K & Gupta, G 2025, 'Formaldehyde and lung cancer' in Lung Cancer and Environmental Toxicants, Elsevier, pp. 177-196.
View/Download from: Publisher's site
Nagar, L, Saini, A, Hussian, T, Gulati, N, Singh, SK, Dua, K & Dureja, H 2025, 'Clinical Trials and Regulatory Issues of Nanocarriers Employed in the Treatment of Chronic Obstructive Pulmonary Disease' in Advanced Drug Delivery Systems in Management of Chronic Obstructive Pulmonary Disease, CRC Press, pp. 239-255.
View/Download from: Publisher's site
Parekh, N, Patel, MN, Nandpal, MN & Dua, K 2025, 'Exploring Proteins and Peptides as Natural Excipients' in Innovative Pharmaceutical Excipients: Natural Sources, Springer Nature Singapore, pp. 147-181.
View/Download from: Publisher's site
Patel, P, Patel, M, Dua, K, Singh, SK & Patel, R 2025, 'Unraveling the potential of curcumin-based nanoformulations: Advancing against multidrug resistance in lung cancer' in Fighting Multidrug Resistance with Herbal Extracts, Essential Oils and Their Components, Elsevier, pp. 499-518.
View/Download from: Publisher's site
Pujari, R, Shilpi, S, Dua, K, Sharma, S & Bhatt, S 2025, 'Tangled Connection of Gut Microbiome and Alzheimer's Disease' in Neuro-Nutraceuticals and Drug Discovery and Delivery in Alzheimer’s Disease, Apple Academic Press, pp. 37-62.
View/Download from: Publisher's site
Subramaniyan, V, Gupta, G, Dua, K, Singh, S, Gowthamarajan, K & Narayana Reddy, VVS 2025, 'The gut reaction: Modulating microbial response to toxicants through diet and lifestyle' in Gut Microbiome and Environmental Toxicants Impact on Human Health, pp. 41-63.
View/Download from: Publisher's site
View description>>
This chapter offers a concise scientific exploration of the intricate relationship between the human microbiome, environmental toxicants, and the impact of dietary and lifestyle choices. Emphasizing the pivotal role of the human microbiome in overall health, the study delves into how lifestyle factors, particularly diet, shape microbial responses to environmental challenges. Focused on the microscopic universe within the body, with the gut as a dynamic hub for diverse microbial communities, the exploration extends beyond bodily confines to investigate complex interactions with environmental toxicants. The study aims to unravel the web of relationships influenced by lifestyle choices, spotlighting practical applications through natural drug molecules like curcumin and substances like karanjin. Curcumin exemplifies its potential to modulate the gut microbiome, fostering a balanced and diverse community essential for overall health. Similarly, karanjin, with antimicrobial properties, emerges as a strategic tool in influencing microbial responses to toxicants, demystifying the human microbiome and emphasizing the role of microbial communities in maintaining physiological harmony. Examples like curcumin and karanjin illustrate the dynamic nature of the microbial universe and its susceptibility to dietary influences. Subsequently, the chapter delves into communication pathways between microbial communities and environmental toxicants, employing real-world examples to illustrate implications for human health. The study concludes by exploring the profound impact of dietary choices on the resilience of the gut microbiome. In summary, this abstract encapsulates the study;s key themes and contributions succinctly.
Subramaniyan, V, Gupta, G, Dua, K, Singh, S, Gowthamarajan, K & Reddy, VVSN 2025, 'The Gut Reaction' in Gut Microbiome and Environmental Toxicants, CRC Press, pp. 41-63.
View/Download from: Publisher's site
Verma, N, Kanojia, N, Thapa, K, Chandel, P & Dua, K 2025, 'Organ-on-a-chip in the diagnosis and treatment of chronic respiratory disorders and its application to advanced drug delivery systems' in Technological Advances and Innovations in the Treatment of Chronic Respiratory Disorders, Elsevier, pp. 267-285.
View/Download from: Publisher's site
Vishwas, S, Khursheed, R, Wadhwa, S, Bashir, B, Gupta, G, Dua, K & Kumar Singh, S 2025, 'Mechanisms of Drug Delivery in Self-Nanoemulsifying Drug Delivery Systems' in Application of Self-Nanoemulsifying Drug Delivery Systems in Inflammatory Diseases, CRC Press, pp. 49-53.
View/Download from: Publisher's site
Yeung, S, Loo, C-Y, Bani Saeid, A & Lee, W-H 2025, 'Current approaches for the treatment of chronic respiratory disorders and limitations' in De Rubis, G, Santos, HA, Suares, D, MacLoughlin, R, Shetty, S & Dua, K (eds), Technological Advances and Innovations in the Treatment of Chronic Respiratory Disorders, Elsevier, pp. 27-49.
View/Download from: Publisher's site
View description>>
The book concludes with a discussion of the current clinical trials and future prospects for the management of CRDs.This is a valuable resource for researchers, clinicians, and other healthcare professionals who are interested in the latest ...
Adam, M, Bain, M, Ashraf, T, Dona, J, Al Zaben, B, Shafik, G, Srikantharajah, R, Kulkarni, MP, Williams, KA, De Rubis, G, Yeung, S, Oliver, BGG & Dua, K 2025, 'Exploring the influence of vaping on the pharmacokinetic fate of inhaled therapeutics', Archives of Toxicology, vol. 99, no. 8, pp. 3133-3145.
View/Download from: Publisher's site
View description>>
Abstract The surge of electronic cigarette use in Australia, especially amongst the younger population, raises significant concerns about its impact on respiratory health. This review focuses on the detrimental effects of vaping on pulmonary function, delving into oxidative stress, ventilation–perfusion mismatching, as well as cellular damage. Our findings show that e-cigarette use adversely affects the pharmacokinetics of inhaled therapies, reducing efficacy through impaired drug distribution, clearance and absorption, as well as alterations in metabolism. These negative effects mirror the impacts of traditional cigarette smoking, posing a severe health risk not only to individuals who vape, but also to those with pre-existing respiratory conditions. Despite its perception as a safer alternative, its consequence on pulmonary health is becoming increasingly evident with issues such as nicotine addiction and emerging evidence that even short-term exposure to e-cigarette aerosols impairs lung function, potentially paving the way for chronic respiratory diseases. This underscores an urgent need for further research on its long-term implications, particularly for individuals relying on inhalation therapies, emphasising the need for informed public health strategies and guiding clinical practice to safeguard respiratory health in this rapidly evolving landscape.
Anderson, BJ, Taylor, SE, Travaglia, J, Catanzariti, RL & Pont, L 2025, 'Trends in the uptake of clinical support pharmacy technician roles in Australian hospitals from 2016 to 2022: a cross‐sectional survey', Journal of Pharmacy Practice and Research, vol. 55, no. 3, pp. 193-203.
View/Download from: Publisher's site
View description>>
AbstractBackgroundA 2016 Australian hospital pharmacy technician workforce survey reported that pharmacy technicians seldom perform clinical support roles. Subsequently, the Society of Hospital Pharmacists of Australia extended their endorsement of pharmacy technicians performing clinical roles in the Standard of practice for pharmacy technicians to support clinical pharmacy services published in 2019. It is unknown if the roles undertaken by hospital pharmacy technicians have since evolved.AimTo compare and contrast trends in the uptake of hospital pharmacy technician roles between 2016–2022.MethodAn electronic questionnaire comprising 97 questions was circulated to Australian hospital pharmacy departments in 2022 and the results were compared to those obtained from the 2016 questionnaire. Hospital pharmacy technicians' clinical support roles were categorised as ‘clinical tasks’ (n = 15) or ‘technical tasks’ (n = 34). Ethical approval was granted by the University of Technology Sydney Human Research Ethics Committee (Reference no: ETH21‐6732) and the study conforms with the National statement on ethical conduct in human research. Informed consent was obtained from all participants via project information distributed to potential participants via email, indicating their participation would be voluntary and anonymous. Participants provided their consent by completing the questionnaire.ResultsResponses were received from 54 of 273 pharmacy departments (response rate 20%) in 2022 compared to 154 responses from 308 pharmacy departments (response rate 50%) in 2016. Hospital pharmacy technicians perfo...
Ashique, S, Mishra, N, Garg, A, Garg, S, Farid, A, Rai, S, Gupta, G, Dua, K, Paudel, KR & Taghizadeh-Hesary, F 2025, 'A Critical Review on the Long-Term COVID-19 Impacts on Patients With Diabetes', The American Journal of Medicine, vol. 138, no. 2, pp. 308-329.
View/Download from: Publisher's site
Bashir, B, Gulati, M, Vishwas, S, Gupta, G, Dhanasekaran, M, Paudel, KR, Chellappan, DK, Anand, K, Negi, P, Singh, PK, Rajput, A, Dua, K & Singh, SK 2025, 'Bridging gap in the treatment of Alzheimer’s disease via postbiotics: Current practices and future prospects', Ageing Research Reviews, vol. 105, pp. 102689-102689.
View/Download from: Publisher's site
Bashir, B, Vishwas, S, Gupta, G, Paudel, KR, Dureja, H, Kumar, P, Cho, H, Sugandhi, VV, Kumbhar, PS, Disouza, J, Dhanasekaran, M, Goh, BH, Gulati, M, Dua, K & Singh, SK 2025, 'Does drug repurposing bridge the gaps in management of Parkinson’s disease? Unravelling the facts and fallacies', Ageing Research Reviews, vol. 105, pp. 102693-102693.
View/Download from: Publisher's site
Benson, H, Heggart, K, Williams, KA, Smit, C & Abela, P 2025, 'Fostering Excellence in Blended Learning, a Mixed Methods Investigation of an Academic Learning Design Support Tool', TechTrends, vol. 69, no. 1, pp. 71-83.
View/Download from: Publisher's site
Bhat, AA, Moglad, E, Afzal, M, Agrawal, N, Thapa, R, Almalki, WH, Kazmi, I, Alzarea, SI, Ali, H, Sharma, S, Singh, SK, Dua, K & Gupta, G 2025, 'The Anticancer Journey of Liquiritin: Insights into Its Mechanisms and Therapeutic Prospects', Current Medicinal Chemistry, vol. 32, no. 28, pp. 6026-6041.
View/Download from: Publisher's site
View description>>
Liquiritin (LIQ), a bioactive flavonoid from Glycyrrhiza species, has shownsignificant potential in cancer therapy. LIQ exhibits potent inhibitory effects on variouscancer cell types, including breast, lung, liver, and colon cancers, while demonstratinglow toxicity towards healthy cells. Its anticancer mechanisms include inducing cell cyclearrest, promoting apoptosis, and modulating inflammation-related pathways. Additionally,LIQ impedes angiogenesis and enhances the efficacy of conventional chemotherapiesthrough sensitization and synergistic effects with other natural compounds and targetedtherapies. These multifaceted actions highlight LIQ as a promising candidate forfurther development as an anticancer agent. This abstract provides an overview of LIQ'schemistry, biological effects, and underlying mechanisms.
Birla, D, Khandale, N, Bashir, B, ShahbazAlam, M, Vishwas, S, Gupta, G, Dureja, H, Kumbhar, PS, Disouza, J, Patravale, V, Veiga, F, Paiva-Santos, AC, Pillappan, R, Paudel, KR, Goh, BH, Singh, M, Dua, K & Singh, SK 2025, 'Application of quality by design in optimization of nanoformulations: Principle, perspectives and practices', Drug Delivery and Translational Research, vol. 15, no. 3, pp. 798-830.
View/Download from: Publisher's site
Chaudhari, S, Dalabehera, M, Subudhi, RN, Dua, K, Kaur, M, Paudel, KR & Kumar, J 2025, 'From nature to nanotech: Unlocking Berberine's therapeutic approaches', Journal of Drug Delivery Science and Technology, vol. 108, pp. 106924-106924.
View/Download from: Publisher's site
Chisari, VA, Benson, H, Benrimoj, SC, Foran, T, Dineen-Griffin, S & Williams, K 2025, 'Pharmacist-prescribed contraception using clinical protocols: A review of the gray literature', Contraception, vol. 149, pp. 110979-110979.
View/Download from: Publisher's site
Couceiro, B, Hameed, H, Vieira, ACF, Singh, SK, Dua, K, Veiga, F, Pires, PC, Ferreira, L & Paiva-Santos, AC 2025, 'Promoting health and sustainability: exploring safer alternatives in cosmetics and regulatory perspectives', Sustainable Chemistry and Pharmacy, vol. 43, pp. 101901-101901.
View/Download from: Publisher's site
De Rubis, G, Paudel, KR, Kokkinis, S, El-Sherkawi, T, Datsyuk, JK, Salunke, P, Gerlach, J & Dua, K 2025, 'Potent phytoceuticals cocktail exhibits anti-inflammatory and antioxidant activity on LPS-triggered RAW264.7 macrophages in vitro', Pathology - Research and Practice, vol. 266, pp. 155770-155770.
View/Download from: Publisher's site
Goyal, R, Kaur, G, Malik, DS, Singh, S, Dua, K, Singh, D & Singh, TG 2025, 'Assessing Anti-Acne Potentials Via In vitro, Ex vivo, and In vivo Models: A Comprehensive Approach', Current Drug Targets, vol. 26, no. 7, pp. 435-453.
View/Download from: Publisher's site
View description>>
Acne vulgaris is the 8th most commonly prevailing skin disorder worldwide. Its pervasivenesshas been predominant in juveniles, especially males, during adolescence and in femalesduring adulthood. The lifestyle and nutrition adopted have been significantly reported to impactthe occurrence and frequency of acne. It typically occurs over the regions of the forehead, upperchest, and back of the body, which are regions with high proportions of active sebaceous follicles.The market today is flooded with the pool of anti-acne medications (oral, topical/systemic) thatcontain either a single therapeutic agent or a blend targeting multiple pathological pathways. However,the clinical applicability of these preparations is limited due to formulation stability, drugpenetrability, and targeting, the incidence of secondary effects, antibiotic resistance, etc. Moreover,the effectiveness of the former therapies varies as per the type and severity of acne. Therefore,it is necessary to extensively research skin physiology under normal and diseased conditionsso that newer, safer, and more effective medications can be devised. Moreover, their safety and efficacyshould be validated by employing various acne models, and their comparative profilingshould be done with standard marketed anti-acne preparations. Acne models assist to uncover thecomplex disease pathogenesis and identify the potential targets for therapeutic interventions. Thisreview is an attempt to highlight varied <i>in vitro, ex vivo</i>, and <i>in vivo</i> testing procedures done to assessdrug efficacy, track disease progression, and compare test substances with existing treatments.By presenting a unified approach to acne modeling, this review will assist researchers in selectingthe most appropriate model for their specific research goals, helping them to generate valuableand reproducible data to support the development of effective acn...
Graham, EL, Amador-Fernández, N, Benrimoj, SI, Martínez-Martínez, F, Palomo-Llinares, R, Sánchez-Tormo, J, Baixauli-Fernández, VJ, Colomer-Molina, V, Pérez-Hoyos, E, Gastelurrutia, MÁ, Cunningham, S & García-Cárdenas, V 2025, 'Unravelling facilitation complexity in community pharmacy: A pragmatic tool for implementation strategy selection', Research in Social and Administrative Pharmacy, vol. 21, no. 5, pp. 408-416.
View/Download from: Publisher's site
Gupta, G, Goyal, A, Ilma, B, Rekha, MM, Nayak, PP, Kaur, M, Khachi, A, Goyal, K, Rana, M, Rekha, A, Chang, D & Dua, K 2025, 'Exosomal miRNAs as biomarkers and therapeutic targets in silicosis-related lung fibrosis', Molecular Biology Reports, vol. 52, no. 1.
View/Download from: Publisher's site
Haysom‐McDowell, A, Paudel, KR, Yeung, S, Kokkinis, S, El Sherkawi, T, Chellappan, DK, Adams, J, Dua, K & De Rubis, G 2025, 'Recent trends and therapeutic potential of phytoceutical‐based nanoparticle delivery systems in mitigating non‐small cell lung cancer', Molecular Oncology, vol. 19, no. 1, pp. 15-36.
View/Download from: Publisher's site
View description>>
Lung cancer is the leading cause of cancer death globally, with non‐small cell lung cancer accounting for the majority (85%) of cases. Standard treatments including chemotherapy and radiotherapy present multiple adverse effects. Medicinal plants, used for centuries, are traditionally processed by methods such as boiling and oral ingestion, However, water solubility, absorption, and hepatic metabolism reduce phytoceutical bioavailability. More recently, isolated molecular compounds from these plants can be extracted with these phytoceuticals administered either individually or as an adjunct with standard therapy. Phytoceuticals have been shown to alleviate symptoms, may reduce dosage of chemotherapy and, in some cases, enhance pharmaceutical mechanisms. Research has identified many phytoceuticals' actions on cancer‐associated pathways, such as oncogenesis, the tumour microenvironment, tumour cell proliferation, metastasis, and apoptosis. The development of novel nanoparticle delivery systems such as solid lipid nanoparticles, liquid crystalline nanoparticles, and liposomes has enhanced the bioavailability and targeted delivery of pharmaceuticals and phytoceuticals. This review explores the biological pathways associated with non‐small cell lung cancer, a diverse range of phytoceuticals, the cancer pathways they act upon, and the pros and cons of several nanoparticle delivery systems.
Hemrajani, C, Negi, P, Garg, P, Agarwal, S, Sharma, A, Dua, K, Chellappan, DK, Singh, SK & Gupta, G 2025, 'Topical astaxanthin via nano flexible membrane vesicles: A new paradigm in atopic dermatitis treatment with immunomodulatory and anti-inflammatory benefits', Journal of Drug Delivery Science and Technology, vol. 112, pp. 107293-107293.
View/Download from: Publisher's site
Hussain, MS, Agrawal, N, Ilma, B, M M, R, Nayak, PP, Kaur, M, Khachi, A, Goyal, K, Rekha, A, Gupta, S, Gupta, G & Dua, K 2025, 'Autophagy and Cellular Senescence in Alzheimer's Disease: Key Drivers of Neurodegeneration', CNS Neuroscience & Therapeutics, vol. 31, no. 7.
View/Download from: Publisher's site
View description>>
ABSTRACTBackgroundAlzheimer's disease (AD) is a progressive neurodegenerative disorder in the elderly, characterized by extracellular amyloid β‑ (Aβ) plaque deposition and intracellular neurofibrillary tangles (NFTs). Impaired autophagy, the cellular pathway for degrading damaged organelles and misfolded proteins, and cellular senescence, permanent cell cycle arrest with proinflammatory secretions, have emerged as key contributors to AD pathogenesis.MethodsWe performed a narrative review of recent mechanistic and preclinical studies investigating (1) autophagic flux and its role in Aβ and tau clearance; (2) the accumulation and secretory phenotype of senescent cells in the aging brain; (3) interactions between autophagy impairment and senescence; and (4) the efficacy of autophagy enhancers (e.g., rapamycin and metformin) and senolytic agents in rodent models of AD.ResultsDefective autophagosome–lysosome fusion in AD causes autophagic vacuole buildup with amyloid precursor protein and β‑secretase, boosting Aβ generation and hindering tau clearance, promoting neurofibrillary tangles. In AD models, senescent neurons and microglia release pro‑inflammatory cytokines (SASP), fueling neuroinflammation and synaptic dysfunction. Decline in autophagy induces senescence and blocks clearance in a vicious cycle. Rapamycin and metformin restore autophagic flux, reduce Aβ and tau pathologies, and improve memory. Senolytics clear senescent cells, reduce inflammation, and rescue cognition.ConclusionDysregulated autophagy and cellular senescence interact to drive the progression of AD. Targeting these pathways with autophagy‐boosting drugs and senolytic agents holds promise for disease‐modifying therapies aimed at halt...
Hussain, MS, Babu, MA, Afzal, M, Roopashree, R, Lal, M, Rekha, A, Oliver, BG, MacLoughlin, R, Chakraborty, A, Dua, K, Ali, H, Shahwan, M & Gupta, G 2025, 'Targeted Protein Degradation in Lung Cancer: The Emerging Role of PROTAC Technology and E3 Ligases', Current Medicinal Chemistry, vol. 32.
View/Download from: Publisher's site
View description>>
Abstract:Lung cancer remains one of the most prevalent and lethal malignancies, withpoor drug response and high mortality rates. Proteolysis-targeting chimeras (PROTACs)are emerging as a novel therapeutic strategy, leveraging E3 ligases to degrade oncogenicproteins selectively via the ubiquitin-proteasome pathway. These degraders offer higherselectivity and bioavailability compared to traditional inhibitors. This review exploreshow PROTACs eliminate oncogenic proteins in lung cancer and examines the role of E3ligases in this process. Commonly utilized ligases include Cereblon (CRBN) and VonHippel-Lindau (VHL), while newer ones, such as MDM2 and Kelch-like ECH-associatedprotein 1 (KEAP1), are being investigated for therapeutic potential. We discuss keyfactors in PROTAC design, including ligand selection, linker optimization, and pharmacokineticproperties, which influence tumor specificity and efficacy while minimizing off-target effects. Additionally, we highlight targetable oncogenic drivers in lung cancer,such as KRAS, EGFR, and ALK fusion proteins, and evaluate preclinical and clinicalstudies that demonstrate PROTACs' potential for overcoming drug resistance. The challengesassociated with clinical translation, tumor microenvironment interactions, and E3ligase selection are also discussed. Finally, we present future perspectives, including expandingthe range of E3 ligases, developing multitargeting strategies, and integratingnext-generation molecular glue degraders. By offering a comparative analysis of E3 ligase-specific PROTACs, this review underscores the potential of PROTAC technology toadvance precision oncology in lung cancer.
Hussain, MS, Goyal, A, Goyal, K, S., RJ, Nellore, J, Shahwan, M, Rekha, A, Ali, H, Dhanasekaran, M, MacLoughlin, R, Dua, K & Gupta, G 2025, 'Targeting CXCR2 signaling in inflammatory lung diseases: neutrophil-driven inflammation and emerging therapies', Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 398, no. 8, pp. 9583-9607.
View/Download from: Publisher's site
Hussain, MS, Mujwar, S, Babu, MA, Goyal, K, Chellappan, DK, Negi, P, Singh, TG, Ali, H, Singh, SK, Dua, K, Gupta, G & Balaraman, AK 2025, 'Pharmacological, computational, and mechanistic insights into triptolide’s role in targeting drug-resistant cancers', Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 398, no. 6, pp. 6509-6530.
View/Download from: Publisher's site
Jamwal, A, Sharma, S, Kapoor, VK, Chauhan, R, Dua, K, Dalwal, V, Kumar, A, Prasher, P & Negi, P 2025, 'From Structure to Function: Isatin Derivatives as a Promising Class of Antiviral Agents', Current Drug Targets, vol. 26, no. 7, pp. 470-488.
View/Download from: Publisher's site
View description>>
A range of heterocyclic compounds, including Isatin (oneH-indole-2, 3-dione) and itsby-products, have been shown to represent potential unit blocks in the synthesis of potential medicinalagents. Numerous studies have been carried out on isatin, its synthesis, biological uses,and its chemical composition since when it was discovered. Functionally, these isatin-containingheterocycles have demonstrated antibacterial, antidiabetic, antiviral, antitubercular, and anticancerproperties, among many others. <i>In vitro</i> and <i>In vivo</i> efficaciousness of several Isatin moieties hasbeen assessed in recent years based on their antimicrobial qualities. Isatin has shown great promiseas a flexible heterocycle in the realm of drug development in recent years. Many viruses havecaused extensive epidemics during the last 50 years, which have had detrimental effects on social,economic, and health conditions. The current unprecedented SARS-CoV-2 epidemic necessitatesintensive research into the development of potent antiviral medications. It has been shown thatIsatin, a flexible heterocycle, has a great deal of potential for drug development. Appropriatelyfunctionalized Isatin compounds have shown noteworthy and extensive antiviral activitiesthroughout the last fifty years. The goal of this study is to gather all known data on Isatin derivatives'antiviral activity, emphasizing their structure-activity correlations as well as research onmechanistic and molecular modelling. We think that the scientific community will find this reviewto be a useful tool in the development of more efficient and powerful antiviral treatmentsbased on Isatin scaffolds.
Kakkar, C, Sharma, V, Mannan, A, Gupta, G, Singh, S, Kumar, P, Dua, K, Kaur, A, Singh, S, Dhiman, S & Singh, TG 2025, 'Diabetic Cardiomyopathy: An Update on Emerging Pathological Mechanisms', Current Cardiology Reviews, vol. 21, no. 2.
View/Download from: Publisher's site
View description>>
Diabetic Cardiomyopathy (DCM) is a notable consequence of diabetes mellitus, distinguishedby cardiac dysfunction that occurs separately from coronary artery disease or hypertension.A recent study has revealed an intricate interaction of pathogenic processes thatcontribute to DCM. Important aspects involve the dysregulation of glucose metabolism, resultingin heightened oxidative stress and impaired mitochondrial function. In addition, persistenthigh blood sugar levels stimulate inflammatory pathways, which contribute to the developmentof heart fibrosis and remodelling. Additionally, changes in the way calcium is managedand the presence of insulin resistance are crucial factors in the formation and advancementof DCM. This may be due to the involvement of many molecular mechanistic pathwayssuch as NLRP3, NF-κB, PKC, and MAPK with their downstream associated signaling pathways.Gaining a comprehensive understanding of these newly identified pathogenic pathwaysis crucial in order to design precise therapy approaches that can enhance the results for individualssuffering from diabetes. In addition, this review offers an in-depth review of not justpathogenic pathways and molecular mechanistic pathways but also diagnostic methods, treatmentoptions, and clinical trials.
Kaur, P, Khan, H, Grewal, AK, Dua, K, Singh, SK, Gupta, G & Singh, TG 2025, 'Exploring Therapeutic Strategies: The Relationship between Metabolic Disorders and FOXO Signalling in Alzheimer's Disease', CNS & Neurological Disorders - Drug Targets, vol. 24, no. 3, pp. 196-207.
View/Download from: Publisher's site
View description>>
Alzheimer’s disease is an ailment that is linked with the degeneration of the brain cells,and this illness is the main cause of dementia. Metabolic stress affects the activity of the brain in ADvia FOXO signaling. The occurrence of AD will significantly surge as the world’s population ages,along with lifestyle changes perceived in current decades, indicating a main contributor to suchaugmented prevalence. Similarly, metabolic disorders of current adulthood, such as obesity, stroke,and diabetes mellitus, have been observed as the risk-causing factors of AD. Environmental influencesinduce genetic mutations that result in the development of several diseases. Metabolic disordersdevelop when individuals are exposed to an environment where food is easily accessible andrequires minimal energy expenditure. Obesity and diabetes are among the most significant worldwidehealth concerns. Obesity arises because of an imbalance between the amount of energy consumedand the amount of energy expended, which is caused by both behavioral and physiologicalfactors. Obesity, insulin resistance syndrome, hypertension, and inflammation are factors that contributeto the worldwide risk of developing diabetes mellitus and neurodegenerative diseases. FOXOtranscription factors are preserved molecules that play an important part in assorted biological progressions,precisely in aging as well as metabolism. Apoptosis, cell division and differentiation, oxidativestress, metabolism, and lifespan are among the physiological processes that the FOXO proteinsare adept at controlling. In this review, we explored the correlation between signaling pathwaysand the cellular functions of FOXO proteins. We have also summarized the intricate role ofFOXO in AD, with a focus on metabolic stress, and discussed the prospect of FOXO as a molecularlink between AD and metabolic disorders.
Khandale, N, Birla, D, Alam, MS, Bashir, B, Vishwas, S, Kumar, A, Potale, Y, Gupta, G, Negi, P, Alam, A, Rehman, ZU, Dua, K, Goh, BH & Singh, SK 2025, 'Quality by design endorsed fabrication of xanthohumol loaded solid nanostructured lipid carrier based powder for effective treatment of Alzheimer's disease in rats', Journal of Drug Delivery Science and Technology, vol. 107, pp. 106792-106792.
View/Download from: Publisher's site
Kolekar, KA, Kumbhar, PS, Vishwas, S, Dua, K & Singh, SK 2025, 'Dissolving microneedles for brain delivery: Recent advances and challenges', Drug Discovery Today, vol. 30, no. 4, pp. 104330-104330.
View/Download from: Publisher's site
Kumbhar, PS, Chavan, R, Darekar, S, Kolekar, K, Sequeira, A, Vishwas, S, Gupta, G, Paudel, KR, Singh, SK, Dua, K, Disouza, J & Patravale, V 2025, 'Bridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are?', Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 398, no. 4, pp. 3213-3240.
View/Download from: Publisher's site
Kumbhar, PS, Kamble, V, Kolekar, KA, Vishwas, S, Kumbhar, P, Patil, KS, Gupta, G, Kharabe, PM, Singh, M, Gurav, S, Chellappan, DK, Singh, SK, Dua, K, Disouza, J & Patravale, V 2025, 'Unraveling the Role of Repurposed Drugs in the Treatment of Acne: Success so Far and the Road Ahead', Drug Development Research, vol. 86, no. 1.
View/Download from: Publisher's site
View description>>
ABSTRACTAcne is a skin disease that impacts 9.4% of the world's population. Available treatments for managing acne include retinoid‐like drugs, antibiotics, corticosteroids, photo, and radiotherapy. Howevere, the aforementioned treatments have certain limitations such as possibility of developing skin cancer from tetracycline, doxycycline, and corticosteroids, microbial resistance to antibiotics, and deadly side effects, and so forth. Repurposing of existing therapeutics having excellent safety profile can be promising way to treat acne efficiently. The repurposed drugs and phytoceuticals from diverse classes have demonstrated promising effects in treating acne. These repurposed drugs have displayed antiacne effectiveness by targeting single or multiple signaling pathways. Various repurposed therapeutics undergoing clinical trials at different phases demonstrated their safety and efficacy in treating acne. Despite being a very good, safe, and less time‐consuming strategy, drug repurposing (DR) faces multiple challenges such as lack of regulatory guidelines, preservation of intellectual property, and clinical validation of claimed therapeutic indication. DR appears to be a viable approach and is likely to offer effective treatment at a reasonable cost in alleviating acne.
Laird, CD, Williams, KA & Benson, H 2025, 'Pharmacists Improving Osteoporosis Management in Long-Term Care Using Fracture Risk Assessments: A Feasibility Study', Journal of the American Medical Directors Association, vol. 26, no. 4, pp. 105494-105494.
View/Download from: Publisher's site
Lambert, M, Taxis, K & Pont, L 2025, 'Impact of Antibiotic Shortages on Antibiotic Utilisation in the Community', Pharmacoepidemiology and Drug Safety, vol. 34, no. 2.
View/Download from: Publisher's site
View description>>
ABSTRACTBackgroundDrug shortages are an increasing and worldwide problem. Oral antibiotics are one of the most used medicines worldwide and have recently been affected by drug shortages. Despite this, little is known about the impact of antibiotic shortages on prescribing practices.AimTo explore the impact of oral antibiotic shortages on national antibiotic utilisation.MethodsA cross‐sectional study of oral antibiotic shortages and antibiotic utilisation was conducted using Australian reimbursement and regulatory data from January 2022 to December 2023. All nationally reimbursed oral antibiotics were included in the study. The number and duration of reported antibiotic shortages per product were determined for each active ingredient. The clinical impact was assessed using national utilisation in Defined Daily Doses per 100 000 inhabitants. Changes in trends were analysed using Joinpoint regression.ResultsShortages were reported for eighteen of the twenty‐one (86%) oral antibiotics reimbursed in Australia. For ten active ingredients, shortages did not coincide with changes in utilisation data. No clear relation between the number and duration of shortages and impact on utilisation was observed. Changes in utilisation coinciding with shortages were observed for eight active ingredients. For cefaclor (−20% decrease in utilisation) and roxithromycin (−26% decrease), the impact of shortages is most clearly reflected by decreases in utilisation. For the other six, minor changes in utilisation were observed coinciding with shortages.ConclusionsAntibiotic shortages were common in Australia during 2022 and 2023. The impact of shortages differs per ...
Loo, C-Y, Traini, D, Young, PM, Yeung, S, Leong, CR & Lee, W-H 2025, 'Evaluation of curcumin nanoparticles of various sizes for targeting multidrug-resistant lung cancer cells via inhalation', Nanomedicine, vol. 20, no. 2, pp. 141-153.
View/Download from: Publisher's site
Lopes, J, Lopes, D, Motallebi, M, Ye, M, Xue, Y, Vieira, ACF, Singh, SK, Dua, K, Veiga, F, Sethi, G, Paiva‐Santos, AC & Makvandi, P 2025, 'Biomembrane‐coated nanosystems as next‐generation delivery systems for the treatment of gastrointestinal cancers', Bioengineering & Translational Medicine, vol. 10, no. 4.
View/Download from: Publisher's site
View description>>
AbstractGastrointestinal cancers, a major global cause of cancer‐related mortality and disease burden, are a heterogeneous group of malignant aliments involving different organs of the digestive system. The late clinical diagnosis, genomic tumor heterogeneity, high complexity of the gastrointestinal tumor microenvironment, along with increasing treatment resistance have been recognized as the main contributing factors to the current inadequacy of the clinical interventions and poor prognosis of the gastrointestinal cancer patients. In the coming years, gastrointestinal cancer‐related global mortality is unfortunately predicted to increase due to the absence of early detection and effective therapeutic options. Biomembrane‐coated biomimetic nanoparticles (NPs) have recently been appointed as advanced nanotechnological tools for the clinical management of gastrointestinal cancers. These comprise not only cell‐mimicking nanodevices (the pioneers of this top‐down coating technology), but also exosome and bacterial mimetics. Due to their enhanced bio‐interfacing features, biocompatibility, immune evasion, and specific targetability to tumorous tissues, these biomimetic nanostructures have been successfully exploited to provide safer, effective, and targeted gastrointestinal cancer applications. This review highlights the latest research on biomembrane‐coated nanosystems for the clinical therapy and diagnosis of the most common and deadliest subtypes of gastrointestinal cancers, namely colorectal cancer, gastric cancer, liver cancer, esophageal cancer, and pancreatic cancer. The current challenges toward their clinical translation are also mentioned.
Madheswaran, T, Chellappan, DK, Lye, FSN & Dua, K 2025, 'Recent advances in the use of liquid crystalline nanoparticles for non-small cell lung cancer treatment', Expert Opinion on Drug Delivery, vol. 22, no. 5, pp. 615-627.
View/Download from: Publisher's site
Mesbahi, Z, Piquer-Martinez, C, Benrimoj, SI, Martinez-Martinez, F, Amador-Fernandez, N, Zarzuelo, MJ, Dineen-Griffin, S & Garcia-Cardenas, V 2025, 'Pharmacists as independent prescribers in community pharmacy: A scoping review', Research in Social and Administrative Pharmacy, vol. 21, no. 3, pp. 142-153.
View/Download from: Publisher's site
Musaie, K, Abbaszadeh, S, Marais, K, Nosrati‐Siahmazgi, V, Rezaei, S, Xiao, B, Dua, K, Santos, HA & Shahbazi, M 2025, 'H2O2‐Generating Advanced Nanomaterials for Cancer Treatment', Advanced Functional Materials, vol. 35, no. 28.
View/Download from: Publisher's site
View description>>
AbstractTumor cells exploit abnormal redox homeostasis and the pro‐tumorigenic effect of reactive oxygen species (ROS) to enhance their survival and progression. However, excessively high levels of ROS can exceed the oxidative stress threshold of tumor cells, inducing cell death. This can occur by selectively elevating the concentration of H2O2 in tumor cells through both endogenous and exogenous mechanisms. The generated H2O2 serves as a precursor for toxic ROS, such as •OH and 1O2, via chemodynamic and photodynamic therapy, respectively, leading to apoptosis, necrosis, and ferroptosis. Strategies to boost H2O2 levels include direct delivery of exogenous H2O2 and amplifying endogenous H2O2 generation by inhibiting antioxidant enzymes, leveraging glucose oxidase, employing photocatalytic therapy (PCT), and utilizing metal peroxides. Among them, metal peroxides have displayed remarkable performance due to their excellent potential to elevate H2O2 concentration within tumor cells while simultaneously normalizing the acidic and hypoxic conditions of the tumor microenvironment (TME). Moreover, these nanostructures enhance tumor sensitivity to complementary treatments, like chemotherapy. This review summarizes advanced perspectives in the design, synthesis, and comparative analysis of H2O2‐generating nanoplatforms, emphasizing their capacity to treat various cancers.
Nagar, L, Gulati, N, Saini, A, Singh, SK, Gupta, G, MacLoughlin, R, Chellappan, DK, Dua, K & Dureja, H 2025, 'Recent Trends and Applications of Nanostructure-based Drug Delivery in Alleviating Chronic Obstructive Pulmonary Disease (COPD)', Current Drug Delivery, vol. 22, no. 6, pp. 708-720.
View/Download from: Publisher's site
View description>>
Chronic Obstructive Pulmonary Disease (COPD), a chronic lung disease that causesbreathing difficulties and obstructs airflow from the lungs, has a significant global health burdenand affects millions of people worldwide. The use of pharmaceuticals in COPD treatment is aimedto alleviate symptoms, improve lung function, prevent exacerbations, and enhance the overall qualityof life for patients. Nanotechnology holds great promise to alleviate the burden of COPD. Themain goal of this review is to present the full spectrum of therapeutics based on nanostructures forthe treatment and management of COPD, including nanoparticles, polymeric nanoparticles, polymericmicelles, solid-lipid nanoparticles, liposomes, exosomes, nanoemulsions, nanosuspensions,and niosomes. Nanotechnology is just one of the many areas of research that may contribute to thedevelopment of more effective and personalized treatment modalities for COPD patients in the future.Future studies may be focused on enhancing the therapeutic effectiveness of nanocarriers byconducting extensive mechanistic investigations to translate current scientific knowledge for theeffective management of COPD with little or no adverse effects.
Nagar, L, Saini, A, Gandhi, L, Awasthi, R, Dua, K & Dureja, H 2025, 'Nanoemulsion-Based Nystatin Delivery: Formulation and Characterization Studies', BioNanoScience, vol. 15, no. 1.
View/Download from: Publisher's site
Pakan, PD, Siu, ACW, Lee, H, Singh, M, De Rubis, G, Yeung, S, Kulkarni, MP, Goh, BH, Hsu, AC, Chellappan, DK, Gupta, G, Yow, Y-Y, Oliver, BGG, Paudel, KR & Dua, K 2025, 'Algal bioactives: Unlocking future frontiers in respiratory therapeutics', Food Bioscience, vol. 69, pp. 106778-106778.
View/Download from: Publisher's site
Parmal, S, Subbappa, P, Nikam, V, Tarwate, Y, Barhate, K, Wagh, S, Gholap, AD, Dua, K, Singh, SK, Parikh, D, Shaikh, M, Khan, TK & Rajput, A 2025, 'Hyaluronic acid based approaches for wound healing: A comprehensive review', International Journal of Biological Macromolecules, vol. 306, pp. 141625-141625.
View/Download from: Publisher's site
Patel, MN, Patel, AJ, Nandpal, MN, Raval, MA, Patel, RJ, Patel, AA, Paudel, KR, Hansbro, PM, Singh, SK, Gupta, G, Dua, K & Patel, SG 2025, 'Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape', Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 398, no. 3, pp. 2127-2150.
View/Download from: Publisher's site
View description>>
Drug-resistant tuberculosis (DR-TB) represents a pressing global health issue, leading to heightened morbidity and mortality. Despite extensive research efforts, the escalation of DR-TB cases underscores the urgent need for enhanced prevention, diagnosis, and treatment strategies. This review delves deep into the molecular and genetic origins of different types of DR-TB, highlighting recent breakthroughs in detection and diagnosis, including Rapid Diagnostic Tests like Xpert Ultra, Whole Genome Sequencing, and AI-based tools along with latest viewpoints on diagnosis and treatment of DR-TB utilizing newer and repurposed drug molecules. Special emphasis is given to the pivotal role of novel drugs and discusses updated treatment regimens endorsed by governing bodies, alongside innovative personalized drug-delivery systems such as nano-carriers, along with an analysis of relevant patents in this area. All the compiled information highlights the inherent challenges of current DR-TB treatments, discussing their complexity, potential side effects, and the socioeconomic strain they impose, particularly in under-resourced regions, emphasizing the cost-effective and accessible solutions. By offering insights, this review aims to serve as a compass for researchers, healthcare practitioners, and policymakers, emphasizing the critical need for ongoing R&D to improve treatments and broaden access to crucial TB interventions.
Poudel, RS, Williams, KA & Pont, LG 2025, 'Tools for Assessing Medication Safety Processes in Nursing Homes: A Systematic Review', Journal of Patient Safety.
View/Download from: Publisher's site
View description>>
Objective: This systematic review aimed to identify tools for measuring the quality of medication safety-related processes in nursing homes. Methods: We systematically searched Medline, Embase, and CINAHL databases to identify studies describing tools for measuring medication safety-related processes or systems supporting medication safety in nursing homes. Databases were searched from their inception to June 2022. For each tool, the individual items included in the tool were mapped to the 9 steps and 3 background processes of the medication management pathway and the methodological quality was assessed using the Appraisal of Indicators through Research and Evaluation (AIRE) Instrument. Results: Four tools for assessing medication safety-related processes or systems in the nursing home setting were identified. The tools varied substantially in terms of development, content (number of key elements and items), focus and quality. Only one tool, the Canadian Medication Safety Self-Assessment for Long-Term Care (MSSA-LTC), addressed all 9 steps and 3 background processes of the medication management pathway and had a high overall quality rating as per the AIRE instrument. Conclusions: While the Canadian MSSA-LTC tool had the widest focus and highest quality of the 4 tools identified, the choice of a tool by an individual nursing home or care organization will depend on the purpose of the assessment and processes of interest as well as the validity of the tool in the jurisdiction in which it is being used. Awareness of the differences and limitations of each tool in the r...
Rajendran, M, Palani, S, Singh, TG, Oliver, B, Dua, K, Subramaniyan, V & Narayanan, K 2025, 'The Dual Role of Conjugated Linoleic Acid in Obesity and Metabolic Disorders', Food Science & Nutrition, vol. 13, no. 7.
View/Download from: Publisher's site
View description>>
ABSTRACTConjugated Linoleic Acid (cis‐9, trans‐11, CLA)/(trans‐10, cis‐12, CLA) has been extensively studied for its role in obesity control and metabolic diseases. This review explores the molecular characteristics of CLA, its metabolic pathways, and its inconsistent effects on lipid metabolism, adipogenesis, energy expenditure, and inflammation. Preclinical and clinical studies suggest that CLA may promote fat oxidation and modulate adipocyte function; however, inconsistent findings highlight dose‐dependent outcomes and individual variability in response. The dual nature of CLA, showing both beneficial and adverse effects, raises questions about its long‐term safety and efficacy. This review critically examines CLA's molecular role in obesity and metabolic regulation, providing insights into its therapeutic promise and limitations. Future research should focus on personalized approaches to CLA supplementation, considering genetic and lifestyle factors for tailored nutritional guidance.
Roy, AA, Pokale, R, Mukharya, A, Nikam, AN, Dua, K, Rao, BSS, Seetharam, RN & Mutalik, S 2025, 'Synergizing CRISPR-Cas9 with Advanced Artificial Intelligence and Machine Learning for Precision Drug Delivery: Technological Nexus and Regulatory Insights', Current Gene Therapy, vol. 25, no. 4, pp. 467-496.
View/Download from: Publisher's site
View description>>
The evolution of genetic exploration tools, from laborious methods like radiationinducedmutations to the transformative CRISPR-Cas9 system, has fundamentally reshaped geneticresearch and gene editing capabilities. This journey, initiated by foundational techniques such asZFNs and TALENs and culminating in the groundbreaking work of Doudna and Charpentier in2012, has ushered in an era of precise DNA alteration and profound insights into gene functions.The CRISPR/Cas9 system uses the Cas9 enzyme and guides RNA (gRNA) to precisely target andcleave DNA, with subsequent repair via error-prone NHEJ or precise HDR, enabling versatile geneediting. Complementary computational tools like E-CRISP and Azimuth 2.0, alongside advanceddeep learning models like DeepCRISPR, have significantly contributed to refining CRISPR experiments,optimizing gRNA efficiency, and predicting outcomes with greater precision. In clinical applications,CRISPR-Cas9 shows great promise for treating complex genetic disorders like sickle celldisease and β-thalassemia, but faces challenges such as off-target effects, immune responses to viralvectors, and ethical issues in germline editing. Overcoming these challenges requires meticulousexperimentation and robust regulatory frameworks to ensure responsible and beneficial utilizationof the CRISPR-Cas9 technology across diverse fields, including cancer treatment, genetic diseasetherapies, agriculture, and synthetic biology, while continually addressing ethical, safety, and legalconsiderations for its advancement and widespread adoption.
Sadique Hussain, M, Gupta, G, Ghaboura, N, Moglad, E, Hassan Almalki, W, Alzarea, SI, Kazmi, I, Ali, H, MacLoughlin, R, Loebenberg, R, Davies, NM, Kumar Singh, S & Dua, K 2025, 'Exosomal ncRNAs in liquid biopsies for lung cancer', Clinica Chimica Acta, vol. 565, pp. 119983-119983.
View/Download from: Publisher's site
Saini, A, Nagar, L, Panwar, R, Pahwa, R, Dua, K, Dureja, H & Verma, PK 2025, 'Nanostructure-Based Drug Delivery in Alleviating Type 2 Diabetes Mellitus', BioNanoScience, vol. 15, no. 1.
View/Download from: Publisher's site
Sanchez-Molina, AI, Benrimoj, SI, Ferri-Garcia, R, Martinez-Martinez, F, Gastelurrutia, MA, Amador-Fernandez, N & Garcia-Cardenas, V 2025, 'Bridging the gap: Enhancing pharmacist-physiscian collaboration through the provision of comprehensive medication reviews in community pharmacy', Exploratory Research in Clinical and Social Pharmacy, vol. 17, pp. 100555-100555.
View/Download from: Publisher's site
Shaikh, MAJ, Gupta, G, Bagiyal, P, Gupta, S, Singh, SK, Pillappan, R, Chellappan, DK, Prasher, P, Jakhmola, V, Singh, TG, Dureja, H, Singh, SK & Dua, K 2025, 'Enhancing drug bioavailability for Parkinson's disease: The promise of chitosan delivery mechanisms', Annales Pharmaceutiques Françaises, vol. 83, no. 2, pp. 195-210.
View/Download from: Publisher's site
Singh, A, Khan, H, Grewal, AK, Dua, K, Singh, SK & Singh, TG 2025, 'Pharmacological Perspective on the Neurobiology of PI3K-Akt-mTOR Signalling in Opioid Dependence', CNS & Neurological Disorders - Drug Targets, vol. 24, no. 9, pp. 652-668.
View/Download from: Publisher's site
View description>>
Opioid addiction is a condition of the central nervous system that occurs as a result of usingopiate-based substances, which can be either natural or synthetic chemicals. These have effectsidentical to those of morphine and work by interacting with opioid receptors such as morphine, heroin,opium, buprenorphine, and Oxycontin. Dopamine has been suggested to play a role in themechanisms linked to opioid addiction. Additionally, neurotransmitters such as serotonin, norepinephrine,glutamate, and GABA may also have a significant impact. These processes play a criticalrole in the formation of brain circuits that are involved in the development of addictive behavior.The PI3K-Akt-mTOR pathway is widely recognized as an essential regulator of the effects inducedby neurotransmitters on synaptic plasticity, protein synthesis, and cellular responses. This interplayhas considerable importance in the development and persistence of opioid addiction, impacting severaldomains, including reward processing, stress reactivity, and brain plasticity. The understandingof these neurochemical modifications provides vital insights into the underlying mechanisms of addictionand presents potential pathways for treatments. The review enlisted the clinical trials of differenttypes of opioid addiction or dependence. The review offers a succinct summary of many studiesthat establish a correlation between the PI3K/Akt-mTOR signaling pathway and various receptorsimplicated in multiple forms of opioid-related dependency.
Singh, R, Farooq, SA, Mannan, A, Garg, N, Devi, S, Dua, K & Singh, TG 2025, 'Murraya koenigii Linn. Modulate diabetic neuropathy via attenuation of mechanical hyperalgesia and allodynia in STZ-induced diabetic rats', Obesity Medicine, vol. 54, pp. 100593-100593.
View/Download from: Publisher's site
Singh, S, Sharma, H, Kumar, V, Gupta, G, Patel, S, Patel, A, Dua, K & Kumar Singh, S 2025, 'Method development and validation on RP-HPLC method for estimation of xanthohumol in nanostructured lipid carriers drug delivery systems', Journal of Chromatography B, vol. 1252, pp. 124437-124437.
View/Download from: Publisher's site
Solanki, N, Saini, S, Singh, SK, Paudel, KR, Goh, BH, Dua, K & Dureja, H 2025, 'Central composite designed boswellic acids loaded nanoparticles for enhanced cellular uptake in human lung cancer cell line A549', Journal of Drug Delivery Science and Technology, vol. 105, pp. 106591-106591.
View/Download from: Publisher's site
Soni, D, Garg, Y, Upadhayay, S, Bhatia, A, Basir, B, Singh, SK, Dua, K & Kumar, P 2025, 'Auranofin-loaded chitosan-lipid hybrid nanoparticle protects against rotenone model of Parkinson's disease via modulation of GSK-3β/ Nrf2/HO-1 signaling', European Journal of Pharmacology, vol. 998, pp. 177523-177523.
View/Download from: Publisher's site
Subedi, S, Guntipally, M, Suwal, N, Thapa, R, Bashyal, S, Panth, N, Gupta, G, MacLoughlin, R, Oliver, B, Dua, K & Paudel, KR 2025, 'Cellular senescence in chronic obstructive pulmonary disease: Molecular mechanisms and therapeutic interventions', Ageing Research Reviews, vol. 110, pp. 102813-102813.
View/Download from: Publisher's site
Suwal, N, Thapa, R, Bashyal, S, Sugandhi, VV, Subedi, S, Panth, N, Amorim, N, Choi, JP, Gupta, M, Idrees, S, Dua, K & Paudel, KR 2025, 'Targeting oncogenic signaling pathways in lung Cancer: The emerging role of nobiletin, a flavonoid from citrus peel', Food Bioscience, vol. 69, pp. 106887-106887.
View/Download from: Publisher's site
Tan, EW, Singh, SK, Dua, K, Gupta, G, Lee, WL, Wong, RSY, Tan, KO & Goh, BH 2025, 'Cancer stem cells: mitochondria signalling pathway and strategies for therapeutic interventions', Molecular Biology Reports, vol. 52, no. 1.
View/Download from: Publisher's site
View description>>
Abstract Cancer stem cells (CSCs) play a critical role in tumor initiation, progression, and resistance to therapy, making them a major hurdle in effective cancer treatment. Unlike bulk cancer cells, CSCs exhibit remarkable adaptability, allowing them to survive under metabolic stress and evade conventional therapies. Mitochondria, as central regulators of cellular metabolism and apoptosis, are integral to CSC function. They facilitate metabolic reprogramming, redox balance, and stress adaptation, thereby enhancing CSC survival, self-renewal, and resistance to treatment. Dysregulated mitochondrial dynamics, including alterations in biogenesis, degradation, and signaling pathways, contribute to CSC maintenance and therapeutic resistance. Furthermore, mitochondrial membrane integrity and oxidative stress regulation determine CSC fate, influencing their ability to withstand chemotherapy and radiotherapy. Recent advances have identified mitochondrial-targeted strategies as promising approaches to impair CSC function and sensitize them to treatment. These include disrupting mitochondrial metabolism, inducing oxidative stress, and modulating mitochondrial quality control mechanisms. By understanding the intricate relationship between mitochondria and CSCs, new therapeutic strategies can be developed to selectively target CSCs, ultimately improving cancer treatment outcomes and preventing disease recurrence. This review provides an in-depth analysis of mitochondrial mechanisms in CSCs and their potential as therapeutic targets.
Thapa, R, Marianesan, AB, Rekha, A, Ganesan, S, Kumari, M, Bhat, AA, Ali, H, Singh, SK, Chakraborty, A, MacLoughlin, R, Gupta, G & Dua, K 2025, 'Hypoxia-inducible factor and cellular senescence in pulmonary aging and disease', Biogerontology, vol. 26, no. 2.
View/Download from: Publisher's site
View description>>
Abstract Cellular senescence and hypoxia-inducible factor (HIF) signaling are crucial in pulmonary aging and age-related lung diseases such as chronic obstructive pulmonary disease idiopathic pulmonary fibrosis and lung cancer. HIF plays a pivotal role in cellular adaptation to hypoxia, regulating processes like angiogenesis, metabolism, and inflammation. Meanwhile, cellular senescence leads to irreversible cell cycle arrest, triggering the senescence-associated secretory phenotype which contributes to chronic inflammation, tissue remodeling, and fibrosis. Dysregulation of these pathways accelerates lung aging and disease progression by promoting oxidative stress, mitochondrial dysfunction, and epigenetic alterations. Recent studies indicate that HIF and senescence interact at multiple levels, where HIF can both induce and suppress senescence, depending on cellular conditions. While transient HIF activation supports tissue repair and stress resistance, chronic dysregulation exacerbates pulmonary pathologies. Furthermore, emerging evidence suggests that targeting HIF and senescence pathways could offer new therapeutic strategies to mitigate age-related lung diseases. This review explores the intricate crosstalk between these mechanisms, shedding light on how their interplay influences pulmonary aging and disease progression. Additionally, we discuss potential interventions, including senolytic therapies and HIF modulators, that could enhance lung health and longevity.
Truong, J, Abu-Suriya, N, Tory, D, Bahho, R, Ismaiel, A, Nguyen, T, Mansour, A, Nand, V, Saponja, J, Dua, K, De Rubis, G & Parisi, D 2025, 'An Exploration of the Interplay Between Caffeine and Antidepressants Through the Lens of Pharmacokinetics and Pharmacodynamics', European Journal of Drug Metabolism and Pharmacokinetics, vol. 50, no. 1, pp. 1-15.
View/Download from: Publisher's site
Vihal, S, Pundir, S, Rathore, C, Ranjan Lal, U, Gupta, G, Kumar Singh, S, Dua, K, Kumar Chellappan, D & Negi, P 2025, 'Nigella sativa Oil-loaded Ethanolic Vesicular Gel for Imiquimod-induced Plaque Psoriasis: Physicochemical Characterization, Rheological Studies, and In vivo Efficacy', Current Drug Delivery, vol. 22, no. 1, pp. 80-91.
View/Download from: Publisher's site
View description>>
Background:The therapeutic effect of NS oil in mild to moderate psoriasis is limited owingto low play load of thymoquinone (<15 %w/w), irritation, dripping, low viscosity and thus, lesscontact time on the lesions.Aims::This study aimed at developing and characterizing the ethanolic vesicular hydrogel system ofNigella sativa (NS) oil (NS EV hydrogel) for the enhancement of anti-psoriatic activity.Objective:The objective of this study was to develop NS EV hydrogel and evaluate its anti-psoriaticactivity.Methods:The identification and quantification of TQ content in different NS seed extracts and marketedoil were measured by an HPTLC method using n-hexane and ethyl acetate as solvent systems.Preparation of ethanolic vesicles (EVs) was performed by solvent injection method, while its antipsoriaticactivity was evaluated employing an Imiquad (IMQ)-induced plaque psoriasis animal model.Results:A compact HPTLC band was obtained for TQ at an Rf value of 0.651. The calibration plotwas linear in the range of 1-10 μg/spot, and the correlation coefficient of 0.990 was indicative ofgood linear dependence of peak area on concentration. From the different NS sources, the high TQcontent was obtained in the marketed cold press oil, i.e., 1.45±0.08mg/ml. Out of various NS oilloadedEVs, the F6 formulation revealed the smallest particle size (278.1nm), with log-normal sizedistribution (0.459) and adequate entrapment efficiency. A non-uniform shape was observed in thetransmission electron microscopy. The viscosity of F6 formulation hydrogel was 32.34 (Pa·s), whichexhibited plastic behavior. In vivo, efficacy studies demonstrated decreased inflammation...
Wabe, N, Urwin, R, Meulenbroeks, I, Seaman, K, Raban, MZ, Neupane, S, Nguyen, A, Silva, SM, Timothy, A, Batool, N, Pont, L & Westbrook, JI 2025, 'Over- and Underuse of Proton Pump Inhibitors in Nursing Homes: A Multisite Longitudinal Cohort Study', Journal of the American Medical Directors Association, vol. 26, no. 2, pp. 105393-105393.
View/Download from: Publisher's site
Wangmo, T, Garg, K, Ibrahim, AA, Srivastava, S, Famta, P, Singh, SK, Gulati, M, Dua, K & Kaur, J 2025, 'Oral insulin delivery by spatiotemporal polymeric Micelles: Existing Barriers, Status Quo and opportunities', European Polymer Journal, vol. 233, pp. 113981-113981.
View/Download from: Publisher's site
Yanadaiah, P, Kumar, GA, Babu, MR, Vishwas, S, Chaitanya, MVNL, Pal, B, Kumar, R, Zandi, M, Gupta, G, MacLoughlin, R, Oliver, BG, Dua, K & Singh, SK 2025, 'Unravelling the Treatment Strategies for Monkeypox Virus: Success and Bottlenecks', Reviews in Medical Virology, vol. 35, no. 4.
View/Download from: Publisher's site
View description>>
ABSTRACTMonkeypox virus (MPXV) is a zoonotic orthopoxvirus (ORXV) that causes a significant public health concern due to its potential for human‐to‐human transmission and ability to cause severe disease. Despite the availability of a vaccine, there is currently no specific antiviral treatment for MPXV. The development of effective therapeutic strategies for MPXV is essential to mitigate its harmful impact on society. Various strategies used to treat the MPXV infection include antiviral drugs, immunoglobulins, and supportive care measures. Antiviral drugs, such as cidofovir, brincidofovir, and tecovirimat, have shown promising results in in vitro and animal models, but their efficacy in human MPXV cases is still uncertain. This article provides a comprehensive review of the therapeutic strategies that have been explored for the management of MPXV virus infection. The review further highlights the challenges and limitations associated with the development and implementation of therapeutic strategies for MPXV.
